Payment overview · 2025
General Payments
$923.44
48 reported records · 16 companies
Healthcare provider profile · identity verified
Bryan M Honaker, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BRANDENBURG, KY · NPI 1356328066
Verified facts
What the public records show
CMS Open Payments records show Bryan M Honaker, M.D. received $923.44 in general payments during 2025 across 48 reported records.
Novo Nordisk Inc accounted for 19.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $183.75 | 19.9% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $172.10 | 18.6% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $143.24 | 15.5% | 7 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $60.93 | 6.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.23 | 5.9% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $48.63 | 5.3% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.33 | 4.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $39.70 | 4.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.39 | 3.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.59 | 3.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.91 | 3.2% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $19.07 | 2.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.26 | 1.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.58 | 1.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.40 | 1.8% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $14.33 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $923.44 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $156.80 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $143.24 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $93.76 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $89.99 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $89.99 | 6 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $60.93 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $54.61 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $48.63 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $43.33 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.70 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.70 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.01 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.01 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.91 | 2 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 33 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 233 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 33 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 108 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 17 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 55 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
70 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
233 | 62 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
55 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
233 | 62 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
52 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
108 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
166 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 931 | 281 |
| Amlodipine Besylate | Amlodipine Besylate | 608 | 182 |
| Lisinopril | Lisinopril | 473 | 150 |
| Pantoprazole Sodium | Pantoprazole Sodium | 460 | 148 |
| Levothyroxine Sodium | Levothyroxine Sodium | 440 | 115 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 430 | 141 |
| Omeprazole | Omeprazole | 394 | 118 |
| Metoprolol Succinate | Metoprolol Succinate | 311 | 115 |
| Tamsulosin Hcl | Tamsulosin Hcl | 281 | 92 |
| Losartan Potassium | Losartan Potassium | 280 | 96 |
| Montelukast Sodium | Montelukast Sodium | 269 | 83 |
| Jardiance | Empagliflozin | 233 | 62 |
| Carvedilol | Carvedilol | 205 | 66 |
| Metformin Hcl | Metformin Hcl | 199 | 61 |
| Furosemide | Furosemide | 186 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 186 | 58 |
| Gabapentin | Gabapentin | 173 | 58 |
| Sertraline Hcl | Sertraline Hcl | 170 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 166 | 46 |
| Eliquis | Apixaban | 166 | 43 |
| Allopurinol | Allopurinol | 161 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 147 | 40 |
| Meloxicam | Meloxicam | 147 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 118 | 41 |
| Famotidine | Famotidine | 116 | 40 |
| Finasteride | Finasteride | 112 | 34 |
| Spironolactone | Spironolactone | 110 | 34 |
| Ozempic | Semaglutide | 108 | 28 |
| Glimepiride | Glimepiride | 101 | 35 |
| Potassium Chloride | Potassium Chloride | 101 | 27 |
| Atenolol | Atenolol | 97 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 96 | 40 |
| Trazodone Hcl | Trazodone Hcl | 90 | 26 |
| Metformin Hcl Er | Metformin Hcl | 84 | 24 |
| Valsartan | Valsartan | 81 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 29 |
| Synthroid | Levothyroxine Sodium | 70 | 23 |
| Buspirone Hcl | Buspirone Hcl | 69 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 18 |
| Ramipril | Ramipril | 63 | 23 |
| Cephalexin | Cephalexin | 61 | 53 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 60 | 55 |
| Pregabalin | Pregabalin | 60 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 58 | 24 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 58 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | 13 |
| Trulicity | Dulaglutide | 52 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 23 |
| Warfarin Sodium | Warfarin Sodium | 50 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 20 |
| Glipizide | Glipizide | 47 | 14 |
| Donepezil Hcl | Donepezil Hcl | 46 | 13 |
| Azithromycin | Azithromycin | 43 | 32 |
| Ezetimibe | Ezetimibe | 41 | 20 |
| Xarelto | Rivaroxaban | 39 | 14 |
| Celecoxib | Celecoxib | 38 | 12 |
| Januvia | Sitagliptin Phosphate | 38 | 11 |
| Prednisone | Prednisone | 38 | 32 |
| Aripiprazole | Aripiprazole | 37 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 13 |
| Simvastatin | Simvastatin | 34 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 34 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | 11 |
| Mounjaro | Tirzepatide | 33 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Brilinta | Ticagrelor | 32 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 19 |
| Ondansetron Odt | Ondansetron | 32 | 19 |
| Irbesartan | Irbesartan | 31 | 11 |
| Valacyclovir | Valacyclovir Hcl | 31 | 20 |
| Alprazolam | Alprazolam | 30 | suppressed |
| Baclofen | Baclofen | 29 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 29 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 24 |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 19 |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 23 |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | 11 |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 18 |
| Methylprednisolone | Methylprednisolone | 26 | 25 |
| Nitroglycerin | Nitroglycerin | 26 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Estradiol | Estradiol | 25 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 25 | 12 |
| Ibuprofen | Ibuprofen | 25 | 14 |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Linzess | Linaclotide | 23 | 11 |
| Fluconazole | Fluconazole | 22 | 16 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | 11 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Nadolol | Nadolol | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $923.44 · 48 records | Novo Nordisk Inc | ABRYSVO, BREZTRI, CAPLYTA, COMIRNATY, CRYSVITA, Cologuard Collection Kit, FARXIGA, GEMTESA, JARDIANCE, Korlym, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TZIELD, UBRELVY, VOQUEZNA, Wegovy, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error